Back to User profile » Dr Sara Cacciapuoti
Papers published by Dr Sara Cacciapuoti:
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study
Megna M, Ruggiero A, Tommasino N, Brescia C, Martora F, Cacciapuoti S, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2024, 17:1037-1042
Published Date: 7 May 2024
The Past, the Present and the Future of Teledermatology: A Narrative Review
Tommasino N, Megna M, Cacciapuoti S, Villani A, Martora F, Ruggiero A, Genco L, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2024, 17:717-723
Published Date: 21 March 2024
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter]
Potestio L, Martora F, Cacciapuoti S, Megna M, Villani A, Ruggiero A
Clinical, Cosmetic and Investigational Dermatology 2024, 17:463-464
Published Date: 24 February 2024
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study
Martora F, Marasca C, Cacciapuoti S, Fariello F, Potestio L, Battista T, Scalvenzi M, Megna M
Clinical, Cosmetic and Investigational Dermatology 2024, 17:159-166
Published Date: 23 January 2024
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review
Potestio L, Martora F, Cacciapuoti S, Megna M, Villani A, Ruggiero A
Clinical, Cosmetic and Investigational Dermatology 2024, 17:51-57
Published Date: 8 January 2024
Herpes Zoster and COVID-19 Vaccination: A Narrative Review
Potestio L, Megna M, Villani A, Cacciapuoti S, Scalvenzi M, Martora F
Clinical, Cosmetic and Investigational Dermatology 2023, 16:3323-3331
Published Date: 16 November 2023
JAK Inhibitors in Psoriatic Disease
Megna M, Potestio L, Ruggiero A, Cacciapuoti S, Maione F, Tasso M, Caso F, Costa L
Clinical, Cosmetic and Investigational Dermatology 2023, 16:3129-3145
Published Date: 31 October 2023
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
Cacciapuoti S, Potestio L, Guerrasio G, Fabbrocini G, Scalvenzi M, Ruggiero A, Caiazzo G, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:2637-2644
Published Date: 25 September 2023
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
Potestio L, Camela E, Cacciapuoti S, Fornaro L, Ruggiero A, Martora F, Battista T, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:2045-2059
Published Date: 4 August 2023
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
Megna M, Camela E, Ruggiero A, Battista T, Martora F, Cacciapuoti S, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2023, 16:1677-1690
Published Date: 28 June 2023
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:529-536
Published Date: 27 February 2023
Tolerability and camouflaging effect of corrective make-up for acne: results of a clinical study of a novel face compact cream
Monfrecola G, Cacciapuoti S, Capasso C, Delfino M, Fabbrocini G
Clinical, Cosmetic and Investigational Dermatology 2016, 9:307-313
Published Date: 11 October 2016